CG Oncology (CGON) Other Non-Current Assets (2023 - 2026)
CG Oncology's (CGON) quarterly Other Non-Current Assets came in at $2.7 million in Q1 2026, up 418.6% YoY from $516000.0 in Q1 2025, and up 59.48% on a QoQ basis from $1.7 million in Q4 2025.
CG Oncology (CGON) Other Non-Current Assets (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Other Non-Current Assets data on file, last reported at $2.7 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 418.6% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (up 418.6% YoY) and the FY2025 annual result came in at $1.7 million, up 1685.11% from the prior year.
- Other Non-Current Assets rose to $2.7 million in Q1 2026, from $1.7 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $2.7 million in Q1 2026 to a low of $19000.0 in Q4 2023.
- A 4-year average of $577800.0 and a median of $104000.0 in 2024 frame the typical range for Other Non-Current Assets.
- The widest YoY moves for Other Non-Current Assets: up 1685.11% in 2025, down 115.09% in 2025.
- Tracing CGON's Other Non-Current Assets over 4 years: stood at $19000.0 in 2023, then surged by 394.74% to $94000.0 in 2024, then surged by 1685.11% to $1.7 million in 2025, then soared by 59.48% to $2.7 million in 2026.
- The last three Other Non-Current Assets figures came in at $2.7 million (Q1 2026), $1.7 million (Q4 2025), and $114000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | 4.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.73 Mn |
| Mar 31, 2026 | 2.68 Mn |
| Dec 31, 2025 | 1.68 Mn |
| Sep 30, 2025 | 114,000.00 |
| Jun 30, 2025 | 522,000.00 |
| Mar 31, 2025 | 516,000.00 |
| Dec 31, 2024 | 94,000.00 |
| Sep 30, 2024 | 53,000.00 |
| Jun 30, 2024 | 53,000.00 |
| Mar 31, 2024 | 53,000.00 |
| Dec 31, 2023 | 19,000.00 |